- Home
- Dp Vii Associates Lp
Insider Trading History of Dp Vii Associates Lp
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Dp Vii Associates Lp since 2008.
The trader's CIK number is 1372932.
At the time of the last reporting, Dp Vii Associates Lp was the 10% Owner of Esperion Therapeutics, Inc.. (stock ticker symbol ESPR).
Also see all insider trading activities at Esperion Therapeutics, Inc..
Note that in the past
DP VII ASSOCIATES LP also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Esperion Therapeutics, Inc. (ESPR) by Dp Vii Associates Lp
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2013 | ESPR | 4,791 | $67,074 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Clovis Oncology, Inc. (CLVS) by Dp Vii Associates Lp
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2011 | CLVS | 15,625 | $203,125 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Zogenix, Inc. (ZGNX) by Dp Vii Associates Lp
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2011 | ZGNX | 58,696 | $117,392 | 0 | $0 | 0 | $0 |
| 2010 | ZGNX | 39,410 | $157,640 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Orexigen Therapeutics, Inc. (OREX) by Dp Vii Associates Lp
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2011 | OREX | 7,882 | $11,428 | 0 | $0 | 0 | $0 |
| 2009 | OREX | 34,524 | $256,639 | 0 | $0 | 0 | $0 |
| 2008 | OREX | 4,064 | $20,035 | 0 | $0 | 0 | $0 |
Insider trading activities at 4 companies by Dp Vii Associates Lp:
1. Esperion Therapeutics, Inc. (ESPR)
2. Clovis Oncology, Inc. (CLVS)
3. Zogenix, Inc. (ZGNX)
4. Orexigen Therapeutics, Inc. (OREX)
Table 1. Insider trading of Esperion Therapeutics, Inc. (ESPR) by Dp Vii Associates Lp
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2013-07-01 | ESPR | Buy | 4,791 | 14.00 | 67,074 |
Table 2. Insider trading of Clovis Oncology, Inc. (CLVS) by Dp Vii Associates Lp
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2011-11-21 | CLVS | Buy | 15,625 | 13.00 | 203,125 |
Table 3. Insider trading of Zogenix, Inc. (ZGNX) by Dp Vii Associates Lp
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2011-09-16 | ZGNX | Buy | 58,696 | 2.00 | 117,392 |
| 2010-11-29 | ZGNX | Buy | 39,410 | 4.00 | 157,640 |
Table 4. Insider trading of Orexigen Therapeutics, Inc. (OREX) by Dp Vii Associates Lp
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2011-12-22 | OREX | Buy | 7,882 | 1.45 | 11,428 |
| 2009-12-18 | OREX | Buy | 639 | 7.50 | 4,792 |
| 2009-12-17 | OREX | Buy | 1,677 | 7.55 | 12,661 |
| 2009-11-24 | OREX | Buy | 839 | 6.75 | 5,663 |
| 2009-11-20 | OREX | Buy | 4,192 | 6.93 | 29,050 |
| 2009-11-23 | OREX | Buy | 2,516 | 6.93 | 17,435 |
| 2009-11-12 | OREX | Buy | 1,040 | 6.90 | 7,176 |
| 2009-11-10 | OREX | Buy | 1,415 | 6.93 | 9,805 |
| 2009-11-11 | OREX | Buy | 899 | 6.93 | 6,230 |
| 2009-08-18 | OREX | Buy | 231 | 7.73 | 1,785 |
| 2009-08-14 | OREX | Buy | 440 | 8.00 | 3,520 |
| 2009-08-17 | OREX | Buy | 1,060 | 7.64 | 8,098 |
| 2009-08-13 | OREX | Buy | 218 | 7.85 | 1,711 |
| 2009-08-12 | OREX | Buy | 6,708 | 8.00 | 53,664 |
| 2009-08-11 | OREX | Buy | 1,749 | 7.60 | 13,292 |
| 2009-07-23 | OREX | Buy | 10,901 | 7.50 | 81,757 |
| 2008-12-09 | OREX | Buy | 4,064 | 4.93 | 20,035 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Dp Vii Associates Lp
(10% Owner of Esperion Therapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.